NZ239617A - Pharmaceutical compositions containing cross-linked homoconjugated monoclonal antibodies having at least two igg antibodies which bind to the same determinant - Google Patents

Pharmaceutical compositions containing cross-linked homoconjugated monoclonal antibodies having at least two igg antibodies which bind to the same determinant

Info

Publication number
NZ239617A
NZ239617A NZ239617A NZ23961791A NZ239617A NZ 239617 A NZ239617 A NZ 239617A NZ 239617 A NZ239617 A NZ 239617A NZ 23961791 A NZ23961791 A NZ 23961791A NZ 239617 A NZ239617 A NZ 239617A
Authority
NZ
New Zealand
Prior art keywords
homoconjugated
bind
linked
pharmaceutical compositions
compositions containing
Prior art date
Application number
NZ239617A
Inventor
Edith Ann Wolff
Howard V Raff
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NZ239617A publication Critical patent/NZ239617A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ239617A 1990-08-31 1991-08-30 Pharmaceutical compositions containing cross-linked homoconjugated monoclonal antibodies having at least two igg antibodies which bind to the same determinant NZ239617A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57572590A 1990-08-31 1990-08-31
US74866291A 1991-08-26 1991-08-26

Publications (1)

Publication Number Publication Date
NZ239617A true NZ239617A (en) 1993-11-25

Family

ID=27076774

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ239617A NZ239617A (en) 1990-08-31 1991-08-30 Pharmaceutical compositions containing cross-linked homoconjugated monoclonal antibodies having at least two igg antibodies which bind to the same determinant

Country Status (11)

Country Link
EP (1) EP0547137A4 (en)
JP (1) JPH06500780A (en)
KR (1) KR930702029A (en)
AU (1) AU8506991A (en)
CA (1) CA2090317A1 (en)
FI (1) FI930846A (en)
IE (1) IE913071A1 (en)
IL (1) IL99363A0 (en)
NZ (1) NZ239617A (en)
PT (1) PT98840A (en)
WO (1) WO1992004053A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2281300A (en) * 1993-08-26 1995-03-01 Merck & Co Inc Anti-HIV antibody oligomer
WO1999002567A2 (en) * 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
EP2845865A1 (en) 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
ES2457072T3 (en) 2006-08-14 2014-04-24 Xencor, Inc. Optimized antibodies that select as target CD19
CA2660795C (en) 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
EP3575317A1 (en) 2007-12-26 2019-12-04 Xencor, Inc. Fc variants with altered binding to fcrn
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010112194A1 (en) 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
MX2011010159A (en) 2009-04-02 2011-10-17 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments.
EP2417159A1 (en) 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-3/anti-c-met antibodies
CN102361883A (en) 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 Bispecific anti-erbb-1/anti-c-met antibodies
JP5616428B2 (en) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト Trivalent bispecific antibody
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011034605A2 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
TWI426920B (en) 2010-03-26 2014-02-21 Hoffmann La Roche Bispecific, bivalent anti-vegf/anti-ang-2 antibodies
AR080793A1 (en) 2010-03-26 2012-05-09 Roche Glycart Ag BISPECIFIC ANTIBODIES
CN103068846B9 (en) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 Bispecific antibodies comprising disulfide-stabilized Fv fragments
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
RU2644341C2 (en) 2012-02-10 2018-02-08 Дженентек, Инк. Single-chain antibodies and other heteromultimers
KR101674784B1 (en) 2012-04-05 2016-11-09 에프. 호프만-라 로슈 아게 Bispecific antibodies against human tweak and human il17 and uses thereof
EP2867253B1 (en) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
CA2871882A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
EP3339328A1 (en) 2012-07-04 2018-06-27 F. Hoffmann-La Roche AG Anti-biotin antibodies and methods of use
CN107973856B (en) 2012-07-04 2021-11-23 弗·哈夫曼-拉罗切有限公司 Covalently linked antigen-antibody conjugates
HUE029435T2 (en) 2012-07-04 2017-02-28 Hoffmann La Roche Anti-theophylline antibodies and methods of use
CN104341504B (en) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 Bispecific antibody
CA2932958A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
MX2016008189A (en) 2014-01-03 2016-09-29 Hoffmann La Roche Covalently linked helicar-anti-helicar antibody conjugates and uses thereof.
CA2930046A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked polypeptide toxin-antibody conjugates
PL3089996T3 (en) 2014-01-03 2021-12-13 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
AR100978A1 (en) 2014-06-26 2016-11-16 Hoffmann La Roche ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME
CN107001482B (en) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 Multispecific antibodies
PL3313877T3 (en) 2015-06-24 2020-11-02 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
CA3081560A1 (en) 2017-11-07 2019-05-16 Hubit Genomix, Inc. Method for primary prevention of allergic disorders during infancy through ige-class-specific immunosuppression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422653D0 (en) * 1984-09-07 1984-10-10 Technology Licence Co Ltd Monoclonal antibodies
WO1991006305A1 (en) * 1989-11-07 1991-05-16 Bristol-Myers Squibb Company Oligomeric immunoglobulins

Also Published As

Publication number Publication date
IE913071A1 (en) 1992-03-11
EP0547137A4 (en) 1993-12-08
KR930702029A (en) 1993-09-08
AU8506991A (en) 1992-03-30
CA2090317A1 (en) 1992-03-01
JPH06500780A (en) 1994-01-27
FI930846A0 (en) 1993-02-25
PT98840A (en) 1992-07-31
IL99363A0 (en) 1992-08-18
WO1992004053A1 (en) 1992-03-19
EP0547137A1 (en) 1993-06-23
FI930846A (en) 1993-04-05

Similar Documents

Publication Publication Date Title
NZ239617A (en) Pharmaceutical compositions containing cross-linked homoconjugated monoclonal antibodies having at least two igg antibodies which bind to the same determinant
NZ236000A (en) Oligomeric monoclonal igg antibody composition
GB2279077B (en) Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha
EP0880597A4 (en) THERAPEUTIC APPLICATIONS FOR THE ANTI-T-BAM (CD40-L) MONOCLONAL ANTIBODY 5c8
IL105541A0 (en) Monoclonal antibodies to gp130 protein,processes for the preparation thereof and pharmaceutical compositions containing the same
AU645187B2 (en) Freeze-dried preparation containing monoclonal antibody
PL311926A1 (en) Anti-alphav-integrinic monoclonal antibodies
EP0636029A4 (en) Antibodies specific for carcinoma-associated antigens.
GB8702689D0 (en) Monoclonal human antibody compositions
EP0578515A3 (en) Humanized monoclonal antibodies.
EP0580859A4 (en) Anti-eda monoclonal antibody
IL90017A0 (en) Monoclonal antibodies
EP0683675A4 (en) Human monoclonal antibodies to cytomegalovirus.
EP0506523A3 (en) Monoclonal antibodies
AU1423892A (en) Monoclonal antibodies directed towards mycobacterial antigens
EP0498767A3 (en) Chimeric antiidiotypic monoclonal antibodies
EP0511300A4 (en) Monoclonal antibody specific for non-immunodominant epitope of hiv proteins
ITMI910491A0 (en) IMMONOTOXIN FROM ANTI-CDS MONOCLONAL ANTIBODIES
EP0508282A3 (en) Anti-idiotypic monoclonal antibodies
EP0513778A3 (en) Hybrid monoclonal antibodies and compositions containing them
GB8927389D0 (en) Monoclonal antibodies
GB8820036D0 (en) Monoclonal antibodies
ZA912136B (en) Anti-oncostatin m monoclonal antibodies
GB9223676D0 (en) Modified antibodies
IL103758A0 (en) Tumor specific monoclonal antibodies